UNSPSC 51372106: Hydrocodone or dihydrocodeinone

This classification denotes an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6YKS4Y3WQ7, chemically known as 4,5-epoxy-3-methoxy-17-methylmorphinan-6-one but generally known as hydrocodone, which bears US NIH Compound Identifier 5284569. European Medicines Agency schedules Hydrocodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08063MIG. The term HYDROCODONE is an International Non-Proprietary Name.

UNSPSC 51372106 Hydrocodone or dihydrocodeinone is a Commodity code that captures state and local procurement of controlled pharmaceutical substances and related harm-reduction products. Recent solicitations under this code show that state and local governments are buying naloxone kits, safe drug deactivation systems, generic pharmaceuticals through cooperative purchasing agreements, and exploring direct-to-manufacturer prescription programs to manage pharmacy costs and support public health initiatives. Issuing bodies span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances—with Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appearing in recent activity. The work ranges from small-scale county procurement of naloxone and drug deactivation systems to large cooperative pharmacy contracts serving multiple state and local entities across regions.

Activity concentrates in Florida, Texas, and Minnesota, with MMCAP's multistate procurement extending to Oregon and other participating jurisdictions. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling the state's intent to bypass traditional pharmacy benefit managers for cost management. MMCAP released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline, requiring vendors to supply through three authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance. Vendors across these solicitations must meet federal regulatory requirements, maintain specific insurance thresholds, and comply with E-Verify and drug-free workplace certifications where required.